Generation, expression and characterization of the humanized K33N monoclonal antibody
The present invention provides humanized antibodies that immunospecifically recognize human 9 integrin. Some of these antibodies inhibit the biological functions of the 9 integrin, thereby exhibiting therapeutic effects on various disorders or diseases that are associated with 9 integrin, including cancer, e.g., the growth and metastasis of a cancer cell, and inflammatory diseases, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease, and so forth.
1. A humanized antibody or an antigen-binding fragment thereof that immunospecifically recognizes human α9 integrin, comprising an H-chain that comprises the amino acid sequence of SEQ ID NO:60 and an L-chain that comprises the amino acid sequence of SEQ ID NO:61.
2. A pharmaceutical composition comprising the humanized antibody or an antigen-binding fragment thereof of claim 1 , and a pharmaceutically acceptable carrier.